<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137770">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01771081</url>
  </required_header>
  <id_info>
    <org_study_id>16459</org_study_id>
    <secondary_id>NN1201</secondary_id>
    <nct_id>NCT01771081</nct_id>
  </id_info>
  <brief_title>Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy</brief_title>
  <acronym>POLARIS</acronym>
  <official_title>POLARIS: A Non-interventional Study in Patients With Diabetic Macular Edema (DME) With Central Involvement to Assess the Effectiveness of Existing Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <authority>France: National Board of Physicians (C.N.O.M &quot;Comité National de l'Ordre des Médecins)</authority>
    <authority>Germany: Ethics Committee</authority>
    <authority>UK: UK Research Ethics Committee, UK National Health Service, Research and Development Department at each site</authority>
    <authority>Italy: Ethics Committee, Italian Authority for Privacy and data Protection (Garante per la Privacy)</authority>
    <authority>Portugal:Ethics Committee</authority>
    <authority>Russia: Ethics Committee</authority>
    <authority>Spain: Ethics Committee</authority>
    <authority>Slovac Republic: Ethics Committee</authority>
    <authority>Greece: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      POLARIS : A non-interventional study in patients with diabetic macular edema (DME) with
      central involvement to assess the effectiveness of existing anti-vascular endothelial growth
      factor (anti-VEGF) treatment regimens.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort</study_design>
  <primary_outcome>
    <measure>Changes in visual acuity, assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) or SNELLEN</measure>
    <time_frame>Baseline, after 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Demographic and clinical characteristics (Age, sex, race, employment status, severity of DME)</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time from diagnosis to first commencement with an approved anti-VEGF therapy</measure>
    <time_frame>Date of first diagnosis; Date of treatment initiation: up to 24 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in retinal thickness, measured by Optical Coherence Tomography (OCT)</measure>
    <time_frame>Baseline, after 12 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of clinically significant macular edema, measured as defined by the ETDRS Research Group</measure>
    <time_frame>Baseline, after each month, up to 12 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resource utilization in terms of treatment choices, frequency and duration</measure>
    <time_frame>Baseline, after 6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in quality of life score (using the NEI VFQ 25), only in countries where used as part of routine practice</measure>
    <time_frame>Baseline, after 6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">807</enrollment>
  <condition>Ophthalmology</condition>
  <condition>Macular Edema</condition>
  <condition>Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Group1</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab (or other DME treatment)</intervention_name>
    <description>Patients with DME having started treatment with an approved anti-VEGF therapy at or after 01 October 2012 and then continuing with this or any kind or no treatment</description>
    <arm_group_label>Group1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        In- and outpatients at participating sites with a diagnosis of DME with central
        involvement. Patients will be enrolled after the decision for treatment with an approved
        anti-VEGF therapy has been made at or after October 2012 by the study physician.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with type 1 or 2 diabetes mellitus

          -  Patients diagnosed with DME with central involvement (defined as the area of the
             center subfield of optical coherence tomography [OCT])

          -  Patients for whom the decision has been made to treat with an approved anti-VEGF
             therapy prior to inclusion into the study

          -  Patients who received the first approved intravitreal anti VEGF treatment from
             October 01, 2012

          -  Patients who give informed consent in writing for study participation

        Exclusion Criteria:

          -  Treatment with any anti-VEGF therapy prior to the start of the observation period
             (October 01, 2012) or enrolment into the study

          -  Participation in an investigational program with interventions out of clinical
             routine practice
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <email>clinical-trials-contact@bayerhealthcare.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 5, 2014</lastchanged_date>
  <firstreceived_date>January 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Longitudinal Studies,</keyword>
  <keyword>Observation</keyword>
  <keyword>Epidemiology</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Endothelial Growth Factors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
